An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria

抗组胺药 医学 内科学 介绍 耐火期 慢性荨麻疹 胃肠病学 麻醉 家庭医学
作者
Sinem Örnek,Cihan Örçen,Martin K. Church,Emek Kocatürk
出处
期刊:International Immunopharmacology [Elsevier BV]
卷期号:112: 109198-109198 被引量:26
标识
DOI:10.1016/j.intimp.2022.109198
摘要

Guidelines recommend standard doses of antihistamines as first-line, and updosing of antihistamines as second-line treatment for the management of chronic urticaria (CU). However, remission rates with different types of first- and second-line treatments and indicators of antihistamine response are largely lacking in the literature.To examine response rates to first- and second-line treatments in CU, and to identify patient characteristics that can predict antihistamine treatment outcomes.We retrospectively analyzed treatment outcomes of 657 CU (556 chronic spontaneous urticaria (CSU), 101 chronic inducible urticaria (CIndU)) patients who had at least 3-months of follow-up data.A standard dose of second generation antihistamines (sgAH) was effective in 43.1 % of the patients. An additional 28.8 % of patients were in remission with second-line treatments. Among patients whose disease was in remission with a standard dose of sgAHs, 14.8 % benefited from switching from their current sgAH to another sgAH. Updosing sgAHs, combination of two different sgAHs, sgAH and first generation H1-antihistamine combination, and sgAH and leukotriene receptor antagonist combination provided remission in 38.3 %, 35.8 %, 37.5 % and 25 % of patients who were given these treatments, respectively. Baseline UCT score ≤ 4, emergency referral and family history of CSU were found to be risk factors for antihistamine refractoriness in patients with CSU.A step-wise approach to the management of CU is practical as more patients respond to treatment at each step. The presence of baseline UCT score ≤ 4, emergency referral and family history of CSU might be helpful to determine patients who require third-line treatments in advance.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传统的八宝粥完成签到 ,获得积分10
刚刚
刘承昭发布了新的文献求助10
刚刚
Willing发布了新的文献求助10
刚刚
刚刚
菜市场买鱼完成签到,获得积分10
1秒前
NexusExplorer的应助被chwa采纳,获得10
1秒前
秋风的应助被syr采纳,获得20
1秒前
莫语发布了新的文献求助10
2秒前
perry完成签到,获得积分10
2秒前
2秒前
EMMACao完成签到,获得积分10
3秒前
充电宝的应助被天真千易采纳,获得10
3秒前
wanci的应助被dhfify采纳,获得10
3秒前
ccc发布了新的文献求助10
3秒前
木木发布了新的文献求助10
3秒前
搜集达人的应助被青柳安采纳,获得10
3秒前
一一发布了新的文献求助40
3秒前
3秒前
3秒前
tyt完成签到 ,获得积分10
3秒前
3秒前
HJJHJH发布了新的文献求助20
3秒前
4秒前
衷燊完成签到,获得积分10
4秒前
岳圆发布了新的文献求助10
4秒前
4秒前
秋叶情安完成签到,获得积分10
4秒前
科研通AI6.2的应助被谨慎芷烟采纳,获得10
4秒前
赘婿的应助被李某某采纳,获得10
5秒前
张大山发布了新的文献求助10
5秒前
京城世界完成签到,获得积分10
5秒前
5秒前
暮冬十二完成签到 ,获得积分10
6秒前
北北完成签到 ,获得积分10
6秒前
6秒前
jiabaili完成签到,获得积分20
6秒前
6秒前
Su完成签到,获得积分10
6秒前
newman发布了新的文献求助10
7秒前
小二郎的应助被刘承昭采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160268
求助须知:如何正确求助?哪些是违规求助? 9555328
关于积分的说明 21727231
捐赠科研通 7750062
什么是DOI,文献DOI怎么找? 3427353
关于科研通互助平台的介绍 2552391
邀请新用户注册赠送积分活动 2471707